-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Pritelivir Mesylate in Genital Herpes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pritelivir Mesylate in Genital Herpes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pritelivir Mesylate in Genital Herpes Drug Details: Pritelivir mesylate (AIC-316, BAY-571293)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRO-1160 in Papillary Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRO-1160 in Papillary Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRO-1160 in Papillary Renal Cell Carcinoma Drug Details: PRO-1160...
-
Product Insights
Herpes Labialis (Oral Herpes) – Drugs In Development, 2023
Global Markets Direct’s, ‘Herpes Labialis (Oral Herpes) - Drugs In Development, 2023’, provides an overview of the Herpes Labialis (Oral Herpes) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Herpes Labialis (Oral Herpes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Genital Herpes – Drugs In Development, 2023
Global Markets Direct’s, ‘Genital Herpes - Drugs In Development, 2023’, provides an overview of the Genital Herpes pipeline landscape. The report provides comprehensive information on the therapeutics under development for Genital Herpes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Hospital Acquired Pneumonia (HAP) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hospital Acquired Pneumonia (HAP) - Drugs In Development, 2023’, provides an overview of the Hospital Acquired Pneumonia (HAP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Simplexvirus (HSV) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Simplexvirus (HSV) Infections - Drugs In Development, 2023’, provides an overview of the Simplexvirus (HSV) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Simplexvirus (HSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Sepsis – Drugs In Development, 2023
Global Markets Direct’s, ‘Sepsis - Drugs In Development, 2023’, provides an overview of the Sepsis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Keratoconjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Keratoconjunctivitis - Drugs In Development, 2023’, provides an overview of the Keratoconjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AD-109 in Obstructive Sleep Apnea
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AD-109 in Obstructive Sleep Apnea report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AD-109 in Obstructive Sleep Apnea Drug Details: AD-109 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pritelivir in Simplexvirus (HSV) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pritelivir in Simplexvirus (HSV) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Pritelivir in Simplexvirus (HSV) Infections Drug Details:Pritelivir (AIC-316, BAY-571293) is under development...